The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are the first direct-to-consumer (DTC) tests authorized by the FDA that provide information on an individual's genetic predisposition to certain medical diseases or conditions, which may help to make decisions about lifestyle choices or to inform discussions with a health care professional.
As many healthcare organizations continue to face a shortage of highly skilled critical care nurses and intensivists, telemedicine has become a crucial element in caring for critically ill patients regardless of location. New data shows Royal Philips (NYSE: PHG, AEX: PHIA), a leading global health technology company, has helped Emory Healthcare to exceed their goals for streamlining the system's ICUs via use of population health solutions.
4 - 6 April 2017, Stuttgart, Germany.
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and PathAI, a company that develops artificial intelligence technology for pathology, are collaborating with the aim to develop solutions that improve the precision and accuracy of routine diagnosis of cancer and other diseases.
Global efforts to enhance clinical engagement and accelerate the impact of digital technology in improving patient care, will be boosted by a new bilateral relationship between two organisations dedicated to supporting effective digital uptake in healthcare.
4 - 6 April 2017, Stuttgart, Germany.
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has signed an agreement to acquire Australian Pharmacy Sleep Services (APSS), a pioneer in pharmacy sleep testing. Headquartered in Sydney, APSS will complement Philips' sleep and respiratory care offering, and will help to accelerate the business' home sleep testing offering through the pharmacy channel in Australia.